Non-tuberculous mycobacterial adenitis is getting more common in our environment. Epidemiologic studies and clinical trials published nowadays are limited. We present a 2-years-old boy diagnosed of Mycobacterium intracellulare adenitis and severe neutropenia as side effect of combined treatment with oral azythromycin and rifabutin, which recovers after suspending the second one. Liver metabolism of macrolide seems to increase other drugs toxicity, in this case, rifabutin. The patient eventually needed surgery due to persistence of the adenitis despite treatment with antibiotics.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4067/S0716-10182015000600016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeting Refractory Triple-Negative Breast Cancer with Sacituzumab Govitecan: A New Era in Precision Medicine.
Cells
December 2024
Department of Nursing, College of Nursing and Health Sciences, Jazan University, Jazan 45142, Saudi Arabia.
Advanced triple-negative breast cancer (TNBC) has poorer outcomes due to its aggressive behavior and restricted therapeutic options. While therapies like checkpoint inhibitors and PARP inhibitors offer some benefits, chemotherapy remains ineffective beyond the first line of treatment. Antibody-drug conjugates (ADCs) like sacituzumab govitecan-hziy (SG) represent a significant advancement.
View Article and Find Full Text PDFFilgrastim Efficiency in Cats Naturally Infected with Feline Panleukopenia Virus.
Animals (Basel)
December 2024
Department of Public Health, Faculty of Veterinary Medicine, "Ion Ionescu de la Brad" Iasi University of Life Sciences, Mihail Sadoveanu Alley, No. 8, 700489 Iasi, Romania.
Feline Panleukopenia (FPL) infection is caused by feline panleukopenia virus (FPV), and it is considered one of the most severe cat's infectious diseases. Since there is no specific antiviral treatment for FPL, the therapeutic protocol usually is focused on fluid therapy and supportive care. However, filgrastim, a granulocyte colony-stimulating factor (G-CSF) used in human medicine to treat neutropenia and leukopenia, has been lately used in treating FPV disease, providing promising results.
View Article and Find Full Text PDFZolbetuximab for Unresectable and Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma: A Review of Literature.
Cureus
December 2024
Subir Chowdhury School of Quality and Reliability, Indian Institute of Technology, Kharagpur, IND.
Article Synopsis
- Zolbetuximab is a chimeric monoclonal antibody designed to target the Claudin 18.2 protein, which is overexpressed in certain gastrointestinal cancers, notably gastric and gastroesophageal junction adenocarcinomas.
- This drug initiates an immune response to attack cancer cells when combined with standard chemotherapy regimens, and it has been approved as a first-line treatment for advanced, unresectable cancers in specific patient populations.
- Clinical trials show that zolbetuximab significantly improves progression-free survival and overall survival rates compared to chemotherapy alone, while maintaining a relatively safe profile for patients.
Evaluation of the consumption pattern and efficacy of Linezolid in COVID-19 hospitalized patients in a hospital in Tehran-Iran.
Daru
January 2025
Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Background: The inappropriate use of antibiotics increases the costs of treatment, antibiotic resistance, increased disease length and duration of hospital stay.
Objectives: The aim of this study was investigating the pattern of use and effectiveness of the Linezolid in COVID-19 hospitalized patients.
Methods: In this retrospective cross-sectional analytical study was carried out from February 2020 (from the beginning of the pandemic in Iran) to the end of September 2020, 32 COVID-19 patients that used Linezolid were included.
Pyrotinib Plus Taxanes or Vinorelbine for the Treatment of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Prospective Evaluation of Efficacy and Safety.
Clin Breast Cancer
December 2024
Department of Chemotherapy, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing Jiangsu China. Electronic address:
Purpose: The clinical benefits of pyrotinib plus taxanes or vinorelbine have not been studied systemically. Consequently, we conducted a prospective evaluation to assess the efficacy and safety of pyrotinib plus taxanes or vinorelbine in patients with human epidermal growth factor 2 (HER2)-positive metastatic breast cancer (MBC).
Methods: Patients with HER2-positive MBC were included to receive pyrotinib combined with taxanes or vinorelbine in Jiangsu Cancer Hospital.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!